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CORRESPO NDENCE
These letters respond to the Commentary ‘Towards responsible use of cognitive-enhancing drugs by the
healthy’ by Henry Greely and colleagues ( Nature 456, 702–705; 2008).

Risks and benefits
may turn out to be
finely balanced
SIR — This Commentary is the
latest in a series of expert-led
deliberations on the prospects
and implications of cognitiveenhancing drugs (see, for
example, refs 1–3). Much of the
debate on enhancement, as
illustrated by the Commentary,
is highly speculative and rests
on assumptions that are not
well grounded in evidence or
experience. There are three key
problematic areas.
First, efficacy — the claimed
and assumed benefits are often
exaggerated. Careful analysis
of trial data suggests that any
cognitive-enhancing effects of
these drugs in healthy humans
are at best modest and mixed,
and at worst little better than
placebo.
Second, safety — very few
drugs are completely without
adverse effects, especially when
used chronically. In the absence
of data on the long-term safety
implications of these drugs,
it is premature to be helping
society “accept the benefits of
enhancement” when the balance
between risk and benefit might be
much narrower than assumed.
Third, demand — there is little
empirical evidence that large
numbers of people will use (or
are interested in using) enhancers
on a routine basis. There is partial
or anecdotal evidence of use in
specific situations (for example,
examinations), but equally,
other partial or anecdotal
evidence suggests considerable
resistance to chronic use among
the general public.
If enough positive assumptions
are made about these key issues,
then almost any technology
can look attractive or inevitable.
The speculation offered in the
Commentary may be of interest to
academic debates in philosophy.
532

But what is needed is realism,
based on a more sober evidencebased assessment that does not
create unrealistic expectations
about either the potential benefits,
or the threats, to individuals and
society.
Simon J. Williams Department of
Sociology, University of Warwick,
Coventry CV4 7AL, UK
e-mail: s.j.williams@warwick.ac.uk
Paul Martin Institute for Science and
Society, University of Nottingham,
University Park, Nottingham
NG7 2RD, UK
1. Academy of Medical Sciences Brain
Science, Addiction and Drugs (A MS,
20 08).
2. British Medical Association Boosting Your
Brain Power: Ethical Aspects of Cognitive
Enhancements (BM A, 20 07).
3. Foresight Drugs Futures 2025? (UK
Department of Trade and Industry,
20 05).

Much ado about
cognitive
enhancement
SIR — Henry Greely and
colleagues call for answers to
several controversial questions
regarding the use of drugs by
healthy people to boost cognitive
performance. The most important
scientific and ethical concern they
raise is safety, not least because
the pressure that leads people to
enhance their performance might
also be a crucial trigger to mental
disorder. This is particularly
likely when combined with sleep
deprivation and anxiety caused
by aggressive competition,
as we have already learned
from the indiscriminate use of
amphetamines.
However, it would not be
surprising if the repurposing
of these drugs has less of
an impact than expected by
some and feared by others.
Myriad personality traits are
just as important as memory
or ‘intelligence’ in the overall
scheme of a successful life.
Studies of gifted or ‘savant’

children show that selfconfidence, discipline, focus,
drive, resilience and social skills
are highly complex personality
traits, often found in successful
people (see, for example,
E. Winner Gifted Children: Myths
and Realities; Basic Books, 1996).
Using medications to improve
cognitive performance might be
relevant in the short term. But a
fully successful future will always
depend on two very singular
human features: eagerness to
excel and setting a high standard
of achievement.
João Ricardo Oliveira Neuropsychiatry
Department and Keizo Asami
Laboratory, Federal University
of Pernambuco, 50670-901,
Recife-PE, Brazil

A medical view
of potential
adverse effects
SIR — Most seasoned physicians
have had the sobering experience
of prescribing medications that,
despite good intentions, caused
bad outcomes. They would call for
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louder notes of caution than those
expressed in this Commentary
when considering the safety of
‘cognitive-enhancing’ drugs such
as Ritalin and Adderall.
The authors do not mention
the US Food and Drug
Administration warning on
the packets of both of these
drugs. Printed in capitals in a
black box, it includes phrases
such as: “amphetamines have
a high potential for abuse.
Administration of amphetamines
for prolonged periods of time
may lead to drug dependence …
Misuse of amphetamine may
cause sudden death and serious
cardiovascular adverse effects.”
This warning does not cover
other rare but serious side
effects, such as Stevens–Johnson
syndrome (a serious skin
reaction) or toxic psychosis.
Furthermore, the incidence of
serious cardiac arrhythmias is
likely to be higher in older people
with incipient cardiovascular
disease — likely consumers of
‘healthy’ enhancement.
Further reason for caution in
advocating neuroenhancers is the
disproportionate advantage the
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Early scientific visitors found mammalian
fossils awaiting discovery in apothecary shops
Xu Xing on the discovery of the Peking Man fossils, page 538

drugs, if effective, would confer
on the wealthy. The authors’
acknowledgment of existing
disturbing inequities does not
mean that we should add more.
A responsible position would
be to call for a moratorium
on the use of enhancers until
enforceable policies to minimize
socioeconomic disparities are
in place, research into the use
and impact of these drugs is
completed, information on
risks and benefits is broadly
disseminated — and physicians,
educators and regulators have
articulated professional normative
positions.
Anjan Chatterjee Department
of Neurology and Center for
Cognitive Neuroscience, University
of Pennsylvania, Philadelphia,
Pennsylvania 19104, USA
e-mail: anjan@mail.med.upenn.edu

Recall of learned
information may rely
on taking drug again
SIR — Henry Greely and
colleagues identify critical
areas of public discussion about
perceptions and use of drugs that
are alleged or expected to improve
cognition.
Stimulants and other drugs
proposed as potential cognitive
enhancers are known to create
profound state dependence, a
phenomenon in which information
or associations learned while
‘under the influence’ of a drug will
later be remembered or used only
when the learner has again taken
the drug. Thus, individuals who
use amphetamines to improve
their learning of new information
may indeed learn slightly faster
or with less effort than those
who do not use such drugs. Later,
however, they may not remember
or use the learned information
unless they take amphetamines or
related drugs again.
How and when state
dependence occurs has been
studied extensively in humans and
other animals, in well-controlled
learning tasks in laboratory

settings. State dependency
of cognitive enhancers would
dramatically influence drug use,
the permanence of learning and
the ability to use information in
new conditions. Indeed, state
dependence can complicate
clinical use of pharmacotherapies
for such disorders as anxiety and
attention-deficit hyperactivity
disorder.
Greely and colleagues note
critical research and policy
questions that societies must
consider to shape expectations
about putative cognitive
enhancers. We urge that the
discussion includes the known
and profound state-dependent
effects of these agents.
Alice M. Young Department of
Pharmacology and Neuroscience,
Texas Tech University Health Sciences
Center, 3601 4th Street, STOP 6592,
Lubbock, Texas 79430, USA
e-mail: alice.young@ttuhsc.edu
Francis C. Colpaert Institut de
Recherche Pierre Fabre, 3, rue des
Satellites, BP 94244, 31432 Toulouse
Cedex 4, France

Patterns of drug
use have varied
throughout history
SIR — Current issues are
assessed by Henry Greely
and colleagues, but their
Commentary contains a bias
consistent with current Western
culture. The use of these drugs
is probably older than recorded
history. They have often been
used regardless of social
convention or rules — and have
had impacts on societies.
In the 1960s, ‘mind-altering
drugs’ had a different connotation
from the present, exemplified by
Timothy Leary’s “Turn on, tune
in and drop out” philosophy.
Drugs such as marijuana and LSD
were said to enhance individual
thinking and creativity, but
research both on the mental
effects of these drugs and on
their use has decreased. Since
then, the use of mind-altering
drugs has shifted towards

enhancing performance, usually
with amphetamine analogues. It
seems that these are becoming
acceptable when used for the
goal of efficient production in
standardized ways.
Don Burnap 11 Oakland Street, Rapid
City, South Dakota 57701, USA

The five preceding letters are a
selection of many comments on this
Commentary that were submitted
to Correspondence. Many other
reactions from readers have
been posted in a long and lively
online discussion forum at Nature
Network, including the following
anonymous contributions.

Careful use helps me
do better research,
and society benefits
SIR — I commend the authors
of this Commentary on what I
think is a fair and insightful piece.
I suspect many of the negative
commenters are guilty of default
outrage without careful thought.
I find that my own occasional,
metered use of these drugs can
make astounding increases in my
ability as a researcher — which
results in tangible benefit to
society. It’s not a competition,
I’m not taking an exam. I’m doing
research; research that I hope
may one day improve the lives of
many. I exercise, sleep, eat well
and I drink coffee. Yet sometimes
that significant extra boost allows
me to spend 12 hours successfully
working through mathematics
that for weeks I was previously
unequal to solving. Why is this the
act of a social criminal?
Current attitudes towards such
drugs seem to be that they are
good if you need them to become
equal, but wrong if you want to
become more than equal. Can
we really be so quick to condemn
a striving to better ourselves?
Should we tell brighter students
to hold back to the median? I
think not. This issue is not black
and white; it requires the careful
grey-scale considerations
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the Commentary authors
recommend.
It is true that many physicians
and biomedical researchers have
placed themselves in quite a
tangled conflict-of-interest web,
and that this compromise can be
dangerous.
Some of the authors of this
Commentary may have some
conflict of interest, which
thankfully Nature requires
authors to disclose. However,
that possible conflict of interest
does not release you, the reader,
from your obligation to rationally
and carefully consider their
argument. They are not wrong just
because some of them consult for
pharmaceutical companies.

Enhancement means
a broader role for
physicians
SIR — This Commentary raises
a wider issue of perceived
responsibility. The traditional
role of physician as healer does
not sit with the category of
enhancement. Plastic surgery
serves as a good analogy here,
with views remaining varied
on the ultimate responsibility.
But with planned, novel,
pharmacological intervention,
physicians must surely be party to
the cause, and thus a broadening
of their role would be necessary.
Ultimately, the call for
risk–benefit research and a fuller
understanding of mechanisms
is therefore welcome, but the
real beneficiaries, at least in
the short term, are likely to be
dominated by the genuinely needy
— neurological and psychiatric
patients. These groups have
had their needs for cognitive
enhancement unmet for far
too long.

Further discussion of the
Commentary and these
Correspondence contributions
is welcome at Nature Network.
Please visit http: // tinyurl.
com /6nyu29 to have your say.
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